Prophylactic Pharmacotherapy for Migraine Headaches

 

 Buy Article Permissions and Reprints

ABSTRACT

Migraine therapeutics are pharmacological, including acute and preventive, nonpharmacological and/or both. Preventive pharmacological strategies serendipitously were discovered to be effective and include drugs from various pharmacological classes (e.g., β-adrenergic blocker, anticonvulsant, tricyclic antidepressants, serotonin receptor antagonist). Converging level I evidence and clinical experience support the use of the antidepressant amitriptyline, the anticonvulsants divalproex and topiramate, and the β-adrenergic blockers propranolol, timolol, and metoprolol in migraine prevention. Other options for migraine prophylaxis exist, but the level of evidence in support of their use is not as robust. All of these drugs have varying degrees of adverse effects, some of which can limit their use. Balancing potential efficacy with risk of adverse effects, addressing patients' expectations and desires, complying with management recommendations, adequate follow up, and accurate assessment of treatment goals are key to migraine prevention. Finally, future migraine-preventive drugs likely will target migraine mechanisms more specifically, which undoubtedly will enhance the therapeutic index.

REFERENCES

• 1 Ramadan N M. Epidemiology and impact of migraine.  Continuum. 2003a;  9-24
  PubMedGoogle Scholar
• 2 Murray C J, Lopez A D. Global mortality, disability, and the contribution of risk factors: global burden of disease study.  Lancet. 1997;  349 1436-1442
  CrossrefPubMedGoogle Scholar
• 3 Ramadan N M. Prophylactic migraine therapy: mechanisms and evidence.  Curr Pain Headache Rep. 2004;  8 91-95
  PubMedGoogle Scholar
• 4 Welch K M, D'Andrea G, Tepley N, Barkley G, Ramadan N M. The concept of migraine as a state of central neuronal hyperexcitability.  Neurol Clin. 1990;  8 817-828
  PubMedGoogle Scholar
• 5 Welch K MA. Contemporary concepts of migraine pathogenesis.  Neurology. 2003;  61(suppl 4) S2-S8
  PubMedGoogle Scholar
• 6 Ramadan N M, Silberstein S D, Freitag F G, Gilbert T T, Frishberg B M. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for the prevention of migraine. U.S. Headache Consortium, 2000. Available at: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf Accessed May 30, 2005
  Google Scholar
• 7 Bigal M E, Krymchantowski A V, Rapoport A M. Prophylactic migraine therapy: emerging treatment options.  Curr Pain Headache Rep. 2004;  8 178-184
  PubMedGoogle Scholar
• 8 Elkind A H, Webster C, Herbertson R K. Efficacy of guafacine in a double-blind parallel study for migraine prophylaxis.  Cephalalgia. 1989;  9(suppl 10) 369-370
  PubMedGoogle Scholar
• 9 Saper J R, Lake III A E, Cantrell D T, Winner P K, White J R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.  Headache. 2002;  42 470-482
  CrossrefPubMedGoogle Scholar
• 10 Kang Y J, Eisenach J C. Intrathecal clonidine reduces hypersensitivity after nerve injury by a mechanism involving spinal m4 muscarinic receptors.  Anesth Analg. 2003;  96 1403-1408
  PubMedGoogle Scholar
• 11 Bender W I. ACE inhibitors for the prophylaxis of migraine headaches.  Headache. 1995;  35 470-471
  CrossrefPubMedGoogle Scholar
• 12 Schrader H, Stovner L J, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo controlled, crossover study.  BMJ. 2001;  322 19-22
  CrossrefPubMedGoogle Scholar
• 13 Paterna S, Di Pasquale P, D'Angelo A et al.. Angiotensin converting enzyme gene deletion polymorphism determines and increase in frequency of migraine attacks in patients suffering from migraine without aura.  Eur Neurol. 2000;  43 133-136
  CrossrefPubMedGoogle Scholar
• 14 Tronvik E, Stovner L J, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.  JAMA. 2003;  289 65-69
  CrossrefPubMedGoogle Scholar
• 15 Ziegler D K, Hurwitz A, Hassanein R S, Kodanaz H A, Preskorn S H, Mason J. Migraine prophylaxis: a comparison of propranolol and amitriptyline.  Arch Neurol. 1987;  44 486-489
  PubMedGoogle Scholar
• 16 Mathew N T. Prophylaxis of migraine and mixed headache: a randomized controlled study.  Headache. 1981;  21 105-109
  CrossrefPubMedGoogle Scholar
• 17 Ozyalcin S N, Talu G K, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine.  Headache. 2005;  45 144-152
  CrossrefPubMedGoogle Scholar
• 18 Krymchantowski A V, Bigal M E, Moreira P F. New and emerging prophylactic agents for migraine.  CNS Drugs. 2002;  16 611-634
  CrossrefPubMedGoogle Scholar
• 19 Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study.  Cephalalgia. 1997;  17 103-108
  CrossrefPubMedGoogle Scholar
• 20 Freitag F G, Collins S D, Carlson H A et al.. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.  Neurology. 2002;  58 1652-1659
  PubMedGoogle Scholar
• 21 Brandes J L, Saper J R, Diamond M et al.. Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
  CrossrefPubMedGoogle Scholar
• 22 Silberstein S D, Neto W, Schmitt J, Jacobs D. MIGR-001 Study Group . Topiramate in migraine prevention: results of a large controlled trial.  Arch Neurol. 2004;  61 490-495
  CrossrefPubMedGoogle Scholar
• 23 Shank R P, Gardocki J F, Streeter A J, Maryanoff B E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.  Epilepsia. 2000;  41(suppl 1) S3-S9
  PubMedGoogle Scholar
• 24 Di Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study.  Clin Ter. 2000;  151 145-148
  PubMedGoogle Scholar
• 25 Mathew N T, Rapoport A, Saper J et al.. Efficacy of gabapentin in migraine prophylaxis.  Headache. 2001;  41 119-128
  PubMedGoogle Scholar
• 26 Brown J P, Dissanayake V U, Briggs A R, Milic M R, Gee N S. Isolation of the [3H]gabapentin-binding protein/alpha 2 delta Ca²⁺ channel subunit from porcine brain: development of a radioligand binding assay for alpha 2 delta subunits using [3H]leucine.  Anal Biochem. 1998;  255 236-243
  CrossrefPubMedGoogle Scholar
• 27 Fink K, Dooley D J, Wolfgang P M et al.. Inhibition of neuronal Ca²⁺ influx by gabapentin and pregabalin in the human neocortex.  Neuropharmacology. 2002;  42 229-236
  CrossrefPubMedGoogle Scholar
• 28 Eckstein-Ludwig U, Fei J, Schwarz W. Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs.  Br J Pharmacol. 1999;  128 92-102
  CrossrefPubMedGoogle Scholar
• 29 Saper J S, Silberstein S, Somogyi M, McCague K. Efficacy and safety of oxcarbazepine in patients with migraine headaches: a multicenter, double-blind, randomized, placebo-controlled study [abstract]. Poster presented at the Annual Meeting of The American Academy of Neurology New Orleans, LA; Poster session April 14, 2005 (P05.152)
  Google Scholar
• 30 Steiner T J, Findley L J, Yuen A W. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.  Cephalalgia. 1997;  17 109-112
  CrossrefPubMedGoogle Scholar
• 31 D'Andrea G, Granella F, Cadaldini M, Manzoni G C. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study.  Cephalalgia. 1999;  19 64-66
  CrossrefPubMedGoogle Scholar
• 32 Ramadan N M, Schultz L L, Gilkey S J. Migraine prophylactic drugs: proof of efficacy, utilization and cost.  Cephalalgia. 1997;  17 73-80
  CrossrefPubMedGoogle Scholar
• 33 Pietrobon D. Calcium channels and channelopathies of the central nervous system.  Mol Neurobiol. 2002;  25 31-50
  PubMedGoogle Scholar
• 34 Omote K, Iwasaki H, Kawamata M, Satoh O, Namiki A. Effects of verapamil on spinal anesthesia with local anesthetics.  Anesth Analg. 1995;  80 444-448
  PubMedGoogle Scholar
• 35 Akerman S, Williamson D J, Goadsby P J. Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.  Br J Pharmacol. 2003;  140 558-566
  CrossrefPubMedGoogle Scholar
• 36 Wallace M S. Calcium and sodium channel antagonists for the treatment of pain.  Clin J Pain. 2000;  16(suppl 2) S80-S85
  PubMedGoogle Scholar
• 37 Knight Y E, Bartsch T, Kaube H, Goadsby P J. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine?.  J Neurosci. 2002;  22 RC213
  PubMedGoogle Scholar
• 38 Ophoff R A, Terwindt G M, Vergouwe M N et al.. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNL1A4.  Cell. 1996;  87 543-552
  CrossrefPubMedGoogle Scholar
• 39 Kors E E, van den Maagdenberg A M, Plomp J J, Frants R R, Ferrari M D. Calcium channel mutations and migraine.  Curr Opin Neurol. 2002;  15 311-316
  CrossrefPubMedGoogle Scholar
• 40 van den Maagdenberg A M, Pietrobon D, Pizzorusso T et al.. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression.  Neuron. 2004;  41 701-710
  CrossrefPubMedGoogle Scholar
• 41 Klapper J, Mathew N T, Abu-Shakra S. Donepezil vs. propranolol for migraine prevention: results of a randomized, controlled, double-blind, double-dummy clinical trial [abstract]. Poster presented at the annual meeting of the American Academy of Neurology New Orleans, LA; Poster session April 14, 2005 (P05.155)
  Google Scholar
• 42 Sandor P S, Afra J. Nonpharmacologic treatment of migraine.  Curr Pain Headache Rep. 2005;  9 202-205
  PubMedGoogle Scholar
• 43 Boska M D, Welch K M, Barker P B, Nelson J A, Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes.  Neurology. 2002;  58 1227-1233
  PubMedGoogle Scholar
• 44 Ramadan N M, Halvorson H, Vande-Linde A, Levine S R, Helpern J A, Welch K M. Low brain magnesium in migraine.  Headache. 1989;  29 590-593
  CrossrefPubMedGoogle Scholar
• 45 Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study.  Cephalalgia. 1996;  16 257-263
  CrossrefPubMedGoogle Scholar
• 46 Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial.  Neurology. 1998;  50 466-470
  CrossrefPubMedGoogle Scholar
• 47 Sandor P S, Di Clemente L, Coppola G et al.. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.  Neurology. 2005;  64 713-715
  CrossrefPubMedGoogle Scholar
• 48 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.  Headache. 2004;  44 885-890
  CrossrefPubMedGoogle Scholar
• 49 Sandor P S, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials.  Headache. 2000;  40 30-35
  CrossrefPubMedGoogle Scholar
• 50 Ciancarelli I, Tozzi-Ciancarelli M G, Di Massimo C, Marini C, Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine.  Cephalalgia. 2003;  23 39-42
  CrossrefPubMedGoogle Scholar
• 51 Tozzi-Ciancarelli M G, De Matteis G, Di Massimo C, Marini C, Ciancarelli I, Carolei A. Oxidative stress and platelet responsiveness in migraine.  Cephalalgia. 1997;  17 580-584
  CrossrefPubMedGoogle Scholar
• 52 Sangiorgi S, Mochi M, Riva R et al.. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura.  Cephalalgia. 1994;  14 21-23
  CrossrefPubMedGoogle Scholar
• 53 Ashkenazi A, Silberstein A D. Botulinum toxin and other new approaches to migraine therapy.  Annu Rev Med. 2004;  55 505-518
  CrossrefPubMedGoogle Scholar
• 54 Blumenfeld A. Botulinum toxin type A for the treatment of headache: pro.  Headache. 2004;  44 825-830
  CrossrefPubMedGoogle Scholar
• 55 Welch K MA. Botulinum toxin type A for the treatment of headache: con.  Headache. 2004;  44 831-833
  CrossrefPubMedGoogle Scholar
• 56 Elkind A H, Friedman A P, Bachman A, Siegelman S S, Sacks O W. Silent retroperitoneal fibrosis associated with methysergide therapy.  JAMA. 1968;  206 1041-1044
  CrossrefPubMedGoogle Scholar
• 57 Curran D A, Lance J W. Clinical trials of methysergide and other preparations in the management of migraine.  J Neurol Neurosurg Psychiatry. 1964;  27 463-469
  PubMedGoogle Scholar
• 58 Terron J A, Bouchelet I, Hamel E. 5-HT7 receptor mRNA expression in human trigeminal ganglia.  Neurosci Lett. 2001;  302 9-12
  CrossrefPubMedGoogle Scholar
• 59 Pittler M H, Ernst E. Feverfew for preventing migraine.  Cochrane Database Syst Rev. 2004;  (1) CD002286
  PubMedGoogle Scholar
• 60 Reuter U, Chiarugi A, Bolay H, Moskowitz M A. Nuclear factor-kappaB as a molecular target for migraine therapy.  Ann Neurol. 2002;  51 507-516
  CrossrefPubMedGoogle Scholar
• 61 Lipton R B, Gobel H, Einhaupl K M, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine.  Neurology. 2004;  63 2240-2244
  CrossrefPubMedGoogle Scholar
• 62 Wang G J, Shum A Y, Lin Y L et al.. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasin, a hypotensive sesquiterpene from petasites formosanus.  J Pharmacol Exp Ther. 2001;  297 240-246
  PubMedGoogle Scholar
• 63 Eaton J. Butterbur, herbal help for migraine.  Natural Pharmacy. 1998;  2 23-24
  PubMedGoogle Scholar

Nabih M RamadanM.D. 

Department of Neurology, The Chicago Medical School at Rosalind Franklin University of Medicine and Science

3333 Green Bay Road, North Chicago, IL 60064